Amarillo Biosciences
OverviewSuggest Edit
Amarillo Biosciences (ABI) is a healthcare company that specializes in the discovery and development of novel biopharmaceuticals, medical treatments, and specialty consumer products. It is engaged in the clinical trials of low-dose oral interferon as a therapeutic treatment for thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV), and influenza indications. In addition, the company develops a treatment to address metabolism related diseases such as T1 and T2 diabetes using a pulsatile insulin infusion therapy that mimics the normal pancreas’ functions.
| Type | Public | |
| Founded | 1984 | |
| HQ | Amarillo, TX, US | Map |
| Website | amarbio.com |
Recent NewsAll News
- Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth
- Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
- Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics
- Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
Key People/Management at Amarillo Biosciences
Stephen T. Chen
Chairman & CEO
Bernard H. Cohen
Vice President
John Junyong Lee
Corporate Legal Counsel
Yasushi Chikagami
Board Member
Daniel Fisher
Board Member
Nicholas Moren
Board Member
Amarillo Biosciences Office Locations
Amarillo Biosciences has offices in Amarillo and Taipei
Amarillo, TX, US (HQ)
4134 Business Park Dr
Taipei, TW
7/F, No. 58, Sec 1, Minsheng East Road Zhongshan District
Amarillo Biosciences Financials and Metrics
Amarillo Biosciences Revenue
Amarillo Biosciences's revenue was reported to be $16.56 k in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 2.1k |
Gross profit (Q1, 2021) | 872.0 |
Gross profit margin (Q1, 2021), % | 41.1% |
Net income (Q1, 2021) | (534.0k) |
EBIT (Q1, 2021) | (522.1k) |
Market capitalization (22-Jul-2021) | 25.2m |
Closing stock price (22-Jul-2021) | 0.9 |
Cash (31-Mar-2021) | 9.4k |
Amarillo Biosciences's current market capitalization is $25.2 m.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 56.6k | 250.0 | 14.9k | 4.1k | 606.0 | 4.8k | 15.2k | 484.0 | 192.0 | 2.1k |
Cost of goods sold | 43.3k | 707.0 | 16.8k | 2.7k | 563.0 | 3.4k | 10.8k | 292.0 | 123.0 | 1.2k |
Gross profit | 13.3k | (457.0) | (1.9k) | 1.4k | 43.0 | 1.4k | 4.4k | 192.0 | 69.0 | 872.0 |
Gross profit Margin, % | 23% | (183%) | (13%) | 33% | 7% | 30% | 29% | 40% | 36% | 41% |
Annual
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (534.0k) | |||||||||
Cash From Operating Activities | (76.5k) | (389.4k) | (697.3k) | (216.2k) | (539.1k) | (779.3k) | (119.5k) | (245.0k) | (408.4k) | (119.5k) |
Capital Expenditures | (4.9k) | (1.6k) | (1.6k) | |||||||
Cash From Investing Activities | (1.7k) | (2.1k) | 55.6k | (1.6k) | (1.6k) | (2.0k) | (1.3k) | (1.9k) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 83.6k |
Debt/Equity | 1.9 x |
Debt/Assets | 0.4 x |
Financial Leverage | 4.9 x |
Amarillo Biosciences Cybersecurity Score
Amarillo Biosciences Online and Social Media Presence
Amarillo Biosciences's Trends
Amarillo Biosciences News and Updates
December 30, 2020
Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth
Amarillo Biosciences, Inc. ("we," "ABI" or the "Company"), (OTC PINK:AMAR), a company engaged in low-dose non-injectable interferon research, announced today that it has entered into a Securities Purchase Agreement ("Agreement") with a strategic investor, Ainos, Inc., a Cayman Islands corporation ("…
September 10, 2020
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Australia and renown pioneer in interferon research, to the C…
August 13, 2020
Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics
Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it is taking steps to reaffirm its position as the world leader in low-dose non-injectable interferon research. ABI will strengthen its commitment to bring its products to market by s…
February 13, 2020
Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of proprietary clinical research information with health offic…
July 29, 2019
Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
Amarillo Biosciences, Inc. (“ABI” or the “Company”), (OTCBB: AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Rep…
August 23, 2018
Amarillo Biosciences First-Half 2018 Business Update
Amarillo Biosciences, Inc. (ABI), (OTCBB: AMAR), a diversified healthcare company, today provided an update on its first-half 2018 results and recent business activities
Amarillo Biosciences Frequently Asked Questions
When was Amarillo Biosciences founded?
Amarillo Biosciences was founded in 1984.
Who are Amarillo Biosciences key executives?
Amarillo Biosciences's key executives are Stephen T. Chen, Bernard H. Cohen and John Junyong Lee.
How many employees does Amarillo Biosciences have?
Amarillo Biosciences has 2 employees.
What is Amarillo Biosciences revenue?
Latest Amarillo Biosciences annual revenue is $16.6 k.
What is Amarillo Biosciences revenue per employee?
Latest Amarillo Biosciences revenue per employee is $8.3 k.
Who are Amarillo Biosciences competitors?
Competitors of Amarillo Biosciences include Zikani Therapeutics, Sentien Biotechnologies and Entera Bio.
Where is Amarillo Biosciences headquarters?
Amarillo Biosciences headquarters is located at 4134 Business Park Dr, Amarillo.
Where are Amarillo Biosciences offices?
Amarillo Biosciences has offices in Amarillo and Taipei.
How many offices does Amarillo Biosciences have?
Amarillo Biosciences has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies